Bonesupport Holding AB (publ) (BONEX.ST)
SEK 382.8
(2.03%)
SEK 382.8
(2.03%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 245.02 Million SEK | 459.44% |
| 2022 | -68.16 Million SEK | 20.3% |
| 2021 | -85.53 Million SEK | 15.66% |
| 2020 | -101.41 Million SEK | 37.03% |
| 2019 | -161.06 Million SEK | 8.7% |
| 2018 | -176.4 Million SEK | -36.89% |
| 2017 | -128.86 Million SEK | -16.95% |
| 2016 | -110.19 Million SEK | -85.02% |
| 2015 | -59.55 Million SEK | -16.63% |
| 2014 | -51.06 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 30.56 Million SEK | 11.46% |
| 2024 Q1 | 21.84 Million SEK | 103.51% |
| 2024 Q2 | 27.42 Million SEK | 25.55% |
| 2023 Q2 | 5.2 Million SEK | 1590.91% |
| 2023 Q4 | 10.73 Million SEK | -95.31% |
| 2023 FY | 245.02 Million SEK | 459.44% |
| 2023 Q1 | 308 Thousand SEK | 101.5% |
| 2023 Q3 | 228.77 Million SEK | 4292.68% |
| 2022 Q3 | -14.95 Million SEK | 8.27% |
| 2022 Q4 | -20.53 Million SEK | -37.32% |
| 2022 FY | -68.16 Million SEK | 20.3% |
| 2022 Q2 | -16.3 Million SEK | 0.43% |
| 2022 Q1 | -16.37 Million SEK | 32.35% |
| 2021 Q2 | -27.04 Million SEK | -33.79% |
| 2021 Q4 | -24.2 Million SEK | -72.04% |
| 2021 Q1 | -20.21 Million SEK | 25.58% |
| 2021 FY | -85.53 Million SEK | 15.66% |
| 2021 Q3 | -14.06 Million SEK | 47.98% |
| 2020 Q1 | -29.38 Million SEK | 28.07% |
| 2020 FY | -101.41 Million SEK | 37.03% |
| 2020 Q4 | -27.16 Million SEK | -27.96% |
| 2020 Q3 | -21.22 Million SEK | 10.18% |
| 2020 Q2 | -23.63 Million SEK | 19.57% |
| 2019 Q1 | -39.08 Million SEK | 16.72% |
| 2019 FY | -161.06 Million SEK | 8.7% |
| 2019 Q4 | -40.84 Million SEK | -23.08% |
| 2019 Q3 | -33.19 Million SEK | 30.77% |
| 2019 Q2 | -47.94 Million SEK | -22.67% |
| 2018 Q4 | -46.92 Million SEK | 18.39% |
| 2018 FY | -176.4 Million SEK | -36.89% |
| 2018 Q1 | -33.77 Million SEK | 34.22% |
| 2018 Q2 | -38.2 Million SEK | -13.1% |
| 2018 Q3 | -57.49 Million SEK | -50.5% |
| 2017 Q3 | -22.88 Million SEK | 2.79% |
| 2017 Q1 | -31.08 Million SEK | 10.27% |
| 2017 Q2 | -23.54 Million SEK | 24.27% |
| 2017 Q4 | -51.35 Million SEK | -124.36% |
| 2017 FY | -128.86 Million SEK | -16.95% |
| 2016 Q2 | -23.27 Million SEK | -33.36% |
| 2016 FY | -110.19 Million SEK | -85.02% |
| 2016 Q4 | -34.64 Million SEK | 0.49% |
| 2016 Q3 | -34.82 Million SEK | -49.62% |
| 2016 Q1 | -17.45 Million SEK | 0.0% |
| 2015 FY | -59.55 Million SEK | -16.63% |
| 2014 FY | -51.06 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AddLife AB (publ) | 190 Million SEK | -28.958% |
| Biotage AB (publ) | 246 Million SEK | 0.398% |
| Doxa AB (publ) | 291.9 Million SEK | 16.06% |
| Elekta AB (publ) | 1.3 Billion SEK | 81.181% |
| iZafe Group AB (publ) | -32.17 Million SEK | 861.526% |
| Ortivus AB (publ) | -18.24 Million SEK | 1442.949% |
| Ortivus AB (publ) | -18.24 Million SEK | 1442.949% |
| Q-linea AB (publ) | -229.36 Million SEK | 206.825% |
| S2Medical AB (publ) | -22.7 Million SEK | 1179.033% |
| Synsam AB (publ) | 311 Million SEK | 21.215% |